LaPointe Christian sold $14K of QSI

LaPointe Christian (GC & Corp. Secretary) sold 15,588 shares of Quantum-Si Inc (QSI) at an average of $0.93 ($0.90–$0.96) across 2 trades over 2026-06-22 to 2026-06-23.

Original reporting
SEC EDGAR · LaPointe Christian
Published Jun 25, 2026, 12:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 12:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QSI
Neutral
medium confidence
Mentioned
$QSI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QSINeutralLow
01

Why it matters

The disclosure updates insider ownership (post-transaction holdings: 1,182,429 shares) and may marginally influence sentiment, but it does not include new operating, financial, or regulatory information.

02

Market read

Primarily a sentiment/flow datapoint; not a fundamental catalyst.

03

What to watch

The dollar value is modest and the filing provides no context on motivations; traders should avoid over-weighting single small insider sales without corroborating fundamentals or guidance changes.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update from SEC EDGAR (filed 2026-06-24)

Background

This is an SEC Form 4 insider transaction for Quantum-Si (QSI) by LaPointe Christian (GC & Corporate Secretary).

Company-level read

Ticker impact

$QSINeutralMedium confidence
Context

Quantum-Si insider LaPointe Christian sold 15,588 shares in open-market trades at ~$0.8990–$0.9574, per Form 4 filed June 24.

Expected impact

Low likelihood of a sustained price move solely from this sale; any impact would be short-lived around the filing/rumor cycle.

Evidence & confidence

The transaction is an open-market sale by an officer/secretary, small in absolute dollar terms (~$14.5k) and explicitly states no pre-arranged 10b5-1 plan, which can slightly increase interpretive sensitivity but remains typically non-material.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply negative outlook; insiders may sell for diversification, taxes, or planned personal liquidity needs.

Key entities

  • Quantum-Si Inc

    Subject of the Form 4 insider sale disclosure.

  • LaPointe Christian

    Officer/Corporate Secretary who sold 15,588 shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QSIMed

Quantum-Si Q3 Earnings Call Highlights

Quantum-Si (QSI) reported Q3 earnings, highlighting progress on its Proteus platform and amino acid detection. The company expects to demonstrate detection of all 20 amino acids by late 2026 and has started a pre-order program. It reduced 2026 expense guidance and maintains sufficient capital for operations until Q4 2028. Supply chain risks are being mitigated. Proteus launch is planned for Q2 2027.

$QSIMed

Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus™ remains on track for anticipated Q2 2027 commercial launch

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus ™ remains on track for anticipated Q2 2027 commercial launch BRANFORD, Conn., November 5, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” o

$QSIMed

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.

$QSIMed

Quantum-Si Q2 Earnings Call Highlights

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.

$QSIMedAI 8/10

Quantum-Si (QSI) Stock Falls on Q2 2026 Earnings

Quantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.